Clinical trials: Normal Pregnancy
Placental Volume
Placental Thickness And Volume Nomogram In Normal Singleton Pregnancies Between 11th And 18th Week Gestational Age
Measurement of placental thickness and volume has a great importance in predicting adverse outcome specially in combination with other markers.
- Trial name
- NCT06561490
- Testing
- sonographic assesment of placental thickness and volume
- Volunteers
- 100 people
- Sponsor
- Sohag University
Soft Tissue Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
This is a phase 1, open-label, single centre study of investigational drug selinexor in participants with soft tissue sarcomas that cannot be treated with standard therapies.
- Conditions
- Soft Tissue Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Leiomyosarcoma, Endometrial Stromal Sarcoma
- Trial name
- NCT04811196
- Testing
- Selinexor
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- University Health Network, Toronto
Atrial Fibrillation, Coronary Heart Disease
EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality
Health inequality and genetic disparity are a significant issue in the United Kingdom (UK). This study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the…
- Conditions
- Atrial Fibrillation, Coronary Heart Disease, Cardiovascular Diseases, Heart Failure
- Trial name
- EMPOWER (NCT03987633)
- Where
- United Kingdom
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Future Genetics Limited
Renal Impairment
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912 in Subjects with Renal Impairment and Matched Control Subjects with Normal Renal Function
- Trial name
- NCT05711381
- Testing
- HM15912
- Where
- 4 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Pelvic Organ Prolapse (POP), Cystocele
Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration
Pelvic organ prolapse (POP) is a condition characterized by descent of vaginal walls, uterus and cervix, or the perineum and causes a sensation of vaginal bulge and pelvic pressure.
- Conditions
- Pelvic Organ Prolapse (POP), Cystocele, Pelvic Floor Disorder
- Trial name
- NCT07544667
- Testing
- Poly-L-Lactic Acid (Sculptra) injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cassandra Kisby
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Polycystic Ovary Syndrome, Metabolic Diseases
Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)
The purpose of this study is to collect data to help understand why some women develop Polycystic Ovary Syndrome (PCOS) associated with decreased lower-body fat.
- Conditions
- Polycystic Ovary Syndrome, Metabolic Diseases, Overweight
- Trial name
- EIFFEL (NCT01745471)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase
TKM 080301 for Primary or Secondary Liver Cancer
Background: Cancer in the liver can start in the liver (e.g., primary liver cancer or hepatocellular cancer) or spread to the liver from cancers in other parts of the body (e.g.
- Conditions
- Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase, Gastric Cancer With Hepatic Metastase, Breast Cancer With Hepatic Metastase
- Trial name
- NCT01437007
- Testing
- TKM-080301
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma, Gastrointestinal Stromal Tumor
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
The purpose of this study is to determine if and how often an unexpected fast increase of disease and complaints shows after stopping the anti-angiogenetic therapy
- Trial name
- NCT00777504
- Testing
- usage oral angiogenesis inhibitor, stop oral angiogenesis inhibitor
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Solid Tumor, Non Small Cell Lung Cancer
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C \& D) to evaluate the safety and…
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT04731467
- Testing
- CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 79 people
- Sponsor
- Famewave Ltd.
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases
NAFLD Among Patients With Type 2 Diabetes and CKD
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases, Type2 Diabetes
- Trial name
- NCT03826381
- Testing
- Magnetic resonance (MR) spectroscopy of the liver, Fibroscan, Continuous glucose monitoring (CGM) for four days.
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Acute Leukemia, Multiple Myeloma
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk.
- Conditions
- Acute Leukemia, Multiple Myeloma, Squamous Cell Carcinoma, Pleural Mesothelioma
- Trial name
- IT-TCP POS (NCT07403630)
- Testing
- Functional tests, Multi-omics analyses, Cytogenetics/ FISH
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Renal Disease, Chronic
Comparison of Infraclavicular Brachial Plexus Block and Local Anesthesia in Arteriovenous Fistula Surgeries and Their Effects on Tissue Oxygen Saturation
In arteriovenous fistula surgery, the effect of infraclavicular brachial plexus block and local anesthesia on tissue oxygenation and the effect of primary patency of the AV fistula is intended to research.
- Trial name
- NCT06416111
- Testing
- NIRS, Pinprick Test, Modified Bromage Scale
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Ankara City Hospital Bilkent
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Healthy, Chronic Kidney Disease
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body
The main objective of this trial is to investigate the influence of moderate and severe renal impairment on the pharmacokinetics of a single dose of BI 764198 in comparison to a group of matched controls with normal renal…
- Trial name
- NCT04176536
- Testing
- BI 764198
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Leiomyoma, Laparoscopy
Combined Vaginal Misoprostol and Perivascular Vasopressin
Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and thereby resulting in less bleeding with removal.
- Conditions
- Leiomyoma, Laparoscopy, Uterine Myomectomy
- Trial name
- NCT03815344
- Testing
- Standard, Standard-vaginal misoprostol
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Antonios Likourezos
Gastrointestinal Cancer, Urologic Cancer
Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors
PALLSOFT is a randomized, open-label, non-inferiority phase III, multicenter, national trial that will investigate whether the patient-reported symptomatic effect of palliative radiotherapy delivered in 1-2 fractions is…
- Conditions
- Gastrointestinal Cancer, Urologic Cancer, Gynecologic Cancer
- Trial name
- PALLSOFT (NCT06398314)
- Testing
- Palliative radiotherapy
- Where
- 11 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Sykehuset Telemark
Stage I Bladder Cancer, Stage II Bladder Cancer
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer
Green tea extract contains ingredients that may slow the growth of certain cancers. It is not yet known whether green tea extract is more effective than a placebo when given before surgery in treating patients with bladder.
- Conditions
- Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
- Trial name
- NCT00666562
- Testing
- Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Leiomyoma, Uterine Fibroids
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
The primary objective of this study is to test the hypothesis that a minimum 75% volume radiofrequency ablation of fibroids associated with menorrhagia results in reduction of menstrual bleeding.
- Conditions
- Leiomyoma, Uterine Fibroids, Menorrhagia
- Trial name
- FAST (NCT00768742)
- Testing
- VizAblate Intrauterine Ultrasound-Guided RF Ablation
- Where
- 3 sites in Canada
- Sponsor
- Gynesonics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.